Objective: Ménière's disease (MD) is a chronic illness characterized by sensorineural hearing loss, recurring vertigo attacks, and tinnitus. It is possibly of multifactorial origin, although several families with autosomal dominant inheritance and reduced penetrance have been described. To elucidate the genetic basis of MD, patients and their families were investigated, and linkage analysis was performed. Study Design: Retrospective and prospective family survey. Patients and Methods: Of 193 patients diagnosed with MD, 37 patients could be ascertained as having a positive family history, which means a frequency of 19.2%. Nineteen families with 81 members (52 positive for MD and 29 negative for MD) were investigated according to the guidelines of the Committee on Hearing and Equilibrium of the American Academy of Otolaryngology. Blood samples were obtained, and a genome-wide linkage analysis was performed with microsatellite markers. Results: Age of onset diminished in subsequent generations. We found suggestive evidence of linkage assuming heterogeneity of MD on chromosome 5 with a maximum multipoint logarithm of the odds of linkage (LOD) score of 1.9 for 13 of 17 families and a potential region on chromosome 12 for 8 families.
Ménière's disease (MD [MIM 156000]) is defined as an entity with initially fluctuating low-frequency hearing loss, recurrent vertigo attacks, aural fullness, and tinnitus. It was first described by Prosper Ménière in 1861 (1) . The cause of the disease is still unknown, although several causes have been suggested, underlining the multifactorial origin: autoimmune mechanisms, altered glycoprotein levels, viral infections, and allergies. The underlying pathophysiological correlate is endolymphatic hydrops as first described by Hallpike and Cairns in 1938 and Kimura and Schuknecht in 1965 (2) . Dysfunction of several structures of the inner ear and especially disturbance of the cochlear fluid homeostasis and the endocochlear potential have been discussed to be involved in the development of MD (3) .
The prevalence of MD has been reported by numerous investigators to be between 17 and 513 of 100,000 individuals depending on the geographical localization of study (4Y6). Bilateral disease is reported to develop in 8% to 20% of cases. Classic MD in children and younger people is only reported in a few rare cases, possibly in the absence of correct interpretation of symptoms (7, 8) .
Inheritance of MD has been described for several times since 1941 by Madeleine Brown (9) . Since then, several further publications supporting a probable autosomal dominant inheritance have followed (8,10Y20) . The frequency of familial disease is suggested to be between 4% and 20%. Anticipation for familial MD (FMD), dependent on the number of MD patients per generation, has been described in numerous pedigrees (10, 11, 14, 16, 20) . In 2007, Klockars and Kentala (21) investigated the inheritance of MD in a Finnish population and reported on 15% of the patients with definite MD representing familial disease. In 1994, 2 working groups proved correlations between MD and HLA genes located on chromosome 6, suggesting a multifactorial cause of MD combined with genetic predisposition (10, 15) .
To date, several authors have mentioned similarities and connections between MD and migraine, an episodic neurovascular disorder characterized by severe often unilateral, pulsatile headache that can be accompanied by nausea, vomiting, photophobia, and/or phonophobia and which lasts several hours to days (International Headache Society) (22) . The attack-like character of both entities and also possible similar pathomechanisms and genetic determinants are discussed (11, 16, 18, 23) . Similar in MD, migraine sporadic types and familiary types of the disease are described. In addition, family clusters of migraine, episodic vertigo, and MD have been observed. Most often, prevalence of migraine within MD families was much higher than in the overall population, approximately 50% in families with FMD in contrast to 17.1% (women) and 5.6% (men) in the overall population (24) .
The discovery of mutations in families with hemiplegic migraine (FHM) in a brain calcium channel gene, CACNA1A, on chromosome 19p13, in ATP1A2 on 1q23, which encodes a certain type of sodium-potassium pumps, and in SCN1A on 2q24, encoding a subunit of a Na v 1.1 voltage-gated sodium channel, as well as approximately 15 other chromosome loci with positive linkage for patients with several types of migraine is of special interest with regard to the pathophysiological mechanisms underlying MD (25Y27).
Probable relations between the gene COCH on chromosome 14q12-q13 and MD also have to be considered (28) . However, investigations by Morrison and Johnson (16) can prove that COCH and the FMD gene in their linkage study were not the same.
Possible new gene locations discussed to data have been DFNA1 (5q31), DFNA6 (4p16), DFNA9 (14q12-13), antiquitin 1 (ATQ1), KCNE1, and the human leukocyte antigene complex HLA (10,15,29Y31) . Nevertheless, a clear correlation between those genes and FMD could not be verified as reproducible. Klar et al. (32) presented a molecular genetic study on 3 families with FMD in 2006, defining a novel candidate region for the disease on chromosome 12p12. However, in another very large family with 5 affected generations, none of the hitherto-known DFNA loci involved in phenotypes resembling MD showed cosegregation with the investigated family (20) .
A general problem in most of the investigations is the definition of MD. Although almost always the criteria of the American Academy of OtolaryngologyYHead and Neck Foundation (AAO-HNS) are cited, often there are patients included only showing ''monosymptomatic'' MD, vertigo or hearing loss, and/or tinnitus, respectively (33) . Because of these poorly defined studies, the resulting numbers concerning frequency of familial and/or isolated MD cannot be always considered as accurate.
We present herein 19 families with 2 to 4 generations positive for definite MD and the results of a complete genome-wide linkage analysis performed in 17 families, which represents one of the biggest collectives of families with MD described to date.
PATIENTS AND METHODS
Between 1989 and 2000, 281 patients with MD were diagnosed according to the guidelines of AAO-HNS and were partially treated at the Department of Otorhinolaryngology, University of Essen. All patients received a questionnaire. The study was reviewed and approved by the ethics committee of the University Hospital Essen. Special emphasis was laid on the age of onset, unilateral or bilateral disease, and on the frequency of additional migraine symptoms in the MD patients themselves or their family members. A total of 193 patients returned the questionnaire, 37 of them reporting a positive family history. Nineteen families were available for complete investigation and blood samples (for detailed information, see Table 1 ). Of these 19 families with 2 or more individuals with FMD and 1 or more healthy relatives, 77 family members were available for personal interview and audiometry (audiometry was usually performed at the department in Essen or by private otolaryngologists if not possible); 4 probands were diagnosed via history from relatives. Fifty-two individuals with definite MD and 29 related individuals reporting no symptoms characteristic of MD were diagnosed.
Ménière's disease was diagnosed according to the guidelines of AAO-HNS. In case migraine or headache symptoms were reported, classification according to the criteria of International Headache Society (IHS) was used (22) . Either all MD individuals received clinical examination with audiometry and vestibulometry in our department or data were available from the patients' otolaryngologists. Four family members living abroad (Switzerland and France) were also visited personally. Data of all patients are documented in Table 1 .
Two families each with 2 MD individuals in 2 different generations were not suitable for linkage analysis and had to be excluded. Consequently, a total number of 17 families could be included into the study. DNA was available from 48 individuals with MD (28 females and 20 males) and 29 healthy related individuals (17 females and 12 males).
Blood samples were obtained from all available family members, who gave written consent, to isolate DNA for linkage analysis. Linkage analysis is a technique that traces patterns of heredity in high-risk families with statistical methods in an attempt to locate a disease-causing gene mutation by identifying marker loci that cosegregate with the disease-predisposing gene. Therefore, DNA of affected as well as nonaffected family members has to be included. This is especially of particular importance in cases of reduced penetrance of the disease because carriers of the mutation might be clinically nonsymptomatic at the time of investigation. DNA was isolated from frozen blood samples by QiAamp Blood Maxi Kit for large genomic and viral DNA purification (Qiagen; Hilden, Germany). A whole-genome scan was performed with 380 microsatellite markers with an average distance of 11 cM. Markers were amplified by polymerase chain reaction in singleplex reactions. Products were pooled and analyzed on MegaBACE-1000 analysis systems (Amersham Biosciences; Freiburg, Germany). Data were analyzed with Genetic Profiler software, version 1.5 (Amersham Biosciences). Two-point LOD score calculations were performed with the program package LINKAGE version 5.2 (34) using 7 different liability classes with penetrances between 55% and 99% and 0.2% phenocopies. Multipoint calculations were performed with the program GeneHunter (35) In 16 of 19 MD families, there were also patients with 1 of the 23 different types of migraine or migraine-like symptoms according to the IHS. Divided into 4 groups, there were 27 patients with MD only, 25 patients with MD and migraine, 7 patients with migraine only, and 22 patients with neither MD nor migraine. In total, 32 (39.5%) of 81 patients from our MD families reported migraine, and the migraine fraction within MD patients (n = 52) was 48.1% (n = 25). Accordingly, familial MD is a suggestive risk factor for migraine (p = 0.057 using Fisher exact test). The proportion of patients with migraine in MD families (39.5%) as well as the proportion of migraine patients with MD from our families (48.1%) is statistically significantly (p = 0.019 in t test) higher than in the average population (11%).
Three selected family trees are shown in Figure 1 , AYC. All of them suggest an autosomal dominant pattern of inheritance with reduced penetrance of MD.
About 1 (sibships) to 4 generations were affected, with 1 to 3 MD members per generation and a maximum of 4 living members with MD per family. The mean age of onset was 69.5 years (range, 61Y85 yr) in generation 1 (n = 20 patients), 49.7 years (range, 18Y80 yr) in generation 2 (n = 23 patients), and only 37.4 years (range, 13Y54 yr) in the following third generation (n = 9 patients). These results show a clear anticipation.
For whole-genome linkage analysis, 17 families were chosen, with a segregation of MD and 2 to 4 affected probands. The linkage study identified 1 chromosomal region suggestive of linkage on chromosome 5 with a maximum multipoint heterogeneity LOD score of 1.9 at > = 0.62 (Fig. 2) . A detailed analysis of the contributions of single families (Fig. 3A) demonstrated that 13 of 17 families were consistent with linkage to the region. The interval around the marker at D5S644, located at 95.8 Mb (GenBank genome build 37.1), is 20 Mb in length and contains 105 known genes and transcripts. The second best heterogeneity LOD score was below the threshold for suggestive linkage. The region is on chromosome 12 (1 = 0.9; > = 0.33) around D12S1684 (77.3 Mb). Eight families were consistent with linkage to the interval, which is 12 Mb in length and contains 67 genes (Fig. 3B) .
DISCUSSION
These results indicate a heterogeneous multifactorial cause with reduced penetrance of FMD. Most patients seem to have an autosomal dominant pattern of MD. The frequency of familial MD, 19.2% in this study, goes along with other investigations describing an incidence between 4% and 20% (17) . The fact that successive generations in family trees with MD have a significantly lower age of onset (anticipation) supports earlier observations (11, 16, 20, 32) . Generation 2 had a mean age of onset of approximately 49.7 years, whereas generation 3 had a mean age of onset of approximately 37.4 years. The youngest patient in this investigation was diagnosed at the age of 13. This is in line with results monitored by Häusler et al. (8) and Choung et al. (7), describing children with MD between 7 and 14 years. It also has to be taken into account that healthy family members, especially the very young ones, might develop MD in the course of their life although presenting without symptoms at time of investigation. The prevalence of migraine in this collective of families with MD (39.5%) is almost as high as the frequency of migraine in families with familial hemiplegic migraine (41%) (23, 36, 37) . To get exact data on the incidence and prevalence of migraine in MD, however, a large survey in a bigger collective should be aimed at. Thus, genetic investigations of MD have to concentrate on the genetic background of migraine as well, which has extensively been summarized by De Vries et al. (27) .
A statement on this question is not yet possible in our collective because there are 23 different types of migraine classified in the IHS. Even familial hemiplegic migraine, which is only 1 type, has been linked to 3 different gene loci: FMH1 on chromosome 19, FMH2 on chromosome 1, and FMH3 on chromosome 2.
Linkage analysis of our patients with MD pointed to regions on chromosome 5 and possibly on chromosome 12. The interval(s) are large and do not contain obvious candidate genes related to those so far known to be involved in familial migraine and/or hearing loss. The potential locus on chromosome 12, with a weakly positive score in our study, is clearly different from the region identified before in 3 families with MD on chromosome 12p12.3 (32) . The analysis of several further families is therefore necessary to confirm the localization of an FMD gene and to narrow down the intervals for mutation studies in positional candidate genes.
However, our study of one of the biggest collectives described to date with patients diagnosed under strict criteria confirmed autosomal dominant inheritance of the disease with genetic heterogeneity and reduced penetrance. Multicenter studies might be necessary to resolve the genetic puzzle of familial and sporadic MD by including many more patients. An alternative would be a genetic association study including several single patientsV although much more expensiveVanalogous to gene mapping, for example, for macular degeneration or migraine, because these entities show similar clinical and genetic properties.
Summing up, a new large region on chromosome 5 and a smaller one on chromosome 12 possibly related to FMD were found. The results of these investigations are very encouraging because they contribute to the still limited knowledge about the basics of FMD and to clarifying the clinical and genetic definitions of the disease.
